Calidi Biotherapeutics (CLDI) Cash from Investing Activities (2022 - 2025)
Calidi Biotherapeutics' quarterly Cash from Investing Activities came in at -$79000.0 in Q4 2025, down 1480.0% year-on-year from $5724.6 in Q4 2024, and down 192.59% quarter-over-quarter from -$27000.0 in Q3 2025.
Calidi Biotherapeutics has reported Cash from Investing Activities for 4 years, with the latest figure at -$79000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities fell 1480.0% year-over-year to -$79000.0; the trailing twelve-month figure through Dec 2025 stood at -$170000.0 (down 962.5% YoY), and the FY2025 full-year result was -$170000.0, down 962.5% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at -$79000.0, down from -$27000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$5000.0 in Q1 2024, with the low at -$333000.0 in Q3 2022.
- Average Cash from Investing Activities over 4 years is -$89076.9, with a median of -$57000.0 recorded in 2025.
- Year-over-year, Cash from Investing Activities soared 96.35% in 2024 and tumbled 1480.0% in 2025.
- Tracing CLDI's Cash from Investing Activities over 4 years: stood at -$161000.0 in 2022, then surged by 78.26% to -$35000.0 in 2023, then soared by 85.71% to -$5000.0 in 2024, then plunged by 1480.0% to -$79000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$79000.0 (Q4 2025), -$27000.0 (Q3 2025), and -$57000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | -428.90 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | -79,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79,000.00 |
| Dec 31, 2025 | -79,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Jun 30, 2025 | -57,000.00 |
| Jun 30, 2025 | -57,000.00 |
| Mar 31, 2025 | -7,000.00 |
| Mar 31, 2025 | -7,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Dec 31, 2023 | -35,000.00 |
| Dec 31, 2023 | -35,000.00 |
| Sep 30, 2023 | -63,000.00 |
| Sep 30, 2023 | -63,000.00 |
| Jun 30, 2023 | -243,000.00 |
| Jun 30, 2023 | -243,000.00 |
| Mar 31, 2023 | -137,000.00 |
| Mar 31, 2023 | -137,000.00 |
| Dec 31, 2022 | -161,000.00 |
| Dec 31, 2022 | -161,000.00 |
| Sep 30, 2022 | -333,000.00 |
| Sep 30, 2022 | -333,000.00 |